X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

Content Team by Content Team
31st March 2023
in Facilities & Operation, News
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform

A £277 million joint government-industry finance package will assist four UK life sciences companies in moving forward with life sciences manufacturing initiatives.

The Life Sciences Innovative Manufacturing Fund (LSIMF) has just released its first round of funding. Government financing of £17 million is supported by a private investment of £260 million. Over 500 jobs will be supported at life sciences businesses across the UK as a result of the funding.

Manufacturing of life sciences is progressing

The following three businesses are being helped by the first round of LSIMF grants:

Ipsen- will get £75 million to expand its manufacturing of breakthrough medications for neurological diseases. This will result in the creation of 39 new jobs and the retention of another 37 at its Wrexham location in North Wales.

Pharmaron- will get aided by £151 million of investment in capital and personnel and will thereby significantly expand operations in Liverpool. This will quadruple the capacity for crucial gene therapy and vaccination components. It will create 174 vacancies while also protecting another 156. Its expansion in Liverpool will contribute to the development of a regional cluster of science-rich skills.

Touchlight will receive a £14 million investment to build commercial-scale manufacturing and also address the production bottleneck of innovative therapeutics such as mRNA vaccines as well as gene and cell therapies. It will establish commercial-scale manufacturing of doggy bone DNA in Hampton, London, thereby creating 17 jobs and protecting another six.

The velocity of change is transforming the industry from AI to biomanufacturing and customised immunotherapies; technologies are merging to produce a new era of advanced digital products, stated George Freeman, State Minister for Science, Research, and Innovation.

It necessitates the creation of new sorts of modern manufacturing units, which is why they went ahead and established the LSIMF, said Freeman.

This will come with an additional £10 million already allocated to Medicines and Healthcare Products Regulatory Agency (MHRA). It will allow the organisation to implement new, faster approval systems beginning in 2024. This would expedite access to technology such as cancer vaccinations and AI medicines for mental health, in addition to currently licenced treatments.

Expanding on previous investments

The Medicines and Diagnostics Manufacturing Transformation Fund- MDMTF is a trial programme that started in April 2021, whose successor happens to be the LSIMF programme. MDMTF provided £75 million in joint public and private funding and also created 224 new vacancies while preserving 345 present ones.

With the increased funding, the two funds have generated £352 million in both public and private investment into the life sciences sector, supporting over 1000 employees.

Previous Post

Nasal Spray Shows Its Effect Against New COVID Variants

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023

Latest News

Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In